CLINICAL TRIAL: A PHASE 2 STUDY OF AZD6244 IN ADVANCED OR METASTATIC HEPATOCELLU

$13,996M01FY2009RRNIH

Virginia Commonwealth University, Richmond VA

Investigators

Linked publications & trials

Paper 38778481 Paper 38225212 Paper 33023400 Paper 28103725 Paper 25783671 Paper 25714579 Paper 25264599 Paper 25248382 Paper 24119188 Paper 23686698 Paper 23515411 Paper 23510278 Paper 23329066 Paper 23315028 Paper 23311611 Paper 23280525 Paper 22917126 Paper 22688849 Paper 22611049 Paper 22532269 Paper 22521357 Paper 22466024 Paper 22458586 Paper 22434223 Paper 22359532 Paper 22349810 Paper 22343513 Paper 22309991 Paper 22228833 Paper 22213086 Paper 22197855 Paper 22103921 Paper 22103814 Paper 22100576 Paper 22045670 Paper 22045667 Paper 22036053 Paper 22030902 Paper 21953442 Paper 21946897 Paper 21931376 Paper 21883917 Paper 21871763 Paper 21856199 Paper 21782771 Paper 21760886 Paper 21757974 Paper 21733508 Paper 21699796 Paper 21557024 Paper 21556038 Paper 21554994 Paper 21526398 Paper 21521847 Paper 21520194 Paper 21515002 Paper 21480316 Paper 21447728 Paper 21440548 Paper 21423719 Paper 21406504 Paper 21376050 Paper 21374690 Paper 21362113 Paper 21335007 Paper 21319198 Paper 21274866 Paper 21224253 Paper 21208761 Paper 21206486 Paper 21176217 Paper 21172393 Paper 21139575 Paper 21136163 Paper 21129375 Paper 21126792 Paper 21114621 Paper 21083592 Paper 20728569 Paper 20684021 Paper 20675691 Paper 20672296 Paper 20648476 Paper 20648472 Paper 20564351 Paper 20427778 Paper 20372110 Paper 20362695 Paper 20359725 Paper 20351741 Paper 20332289 Paper 20301112 Paper 20211180 Paper 20178797 Paper 20132120 Paper 20132119 Paper 20132118 Paper 20101752 Paper 20070284 Paper 20044810

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Studies of primary tumor samples and cell lines have shown constituitive activation or over-activation of the MAP kinase pathways in cancers of the pancreas, colon, lung, ovary and kidney. Therefore agents targeting the RAS/RAF/MEK/EFK pathway might inhibit oncogenic signalling in tumor cells.

View original record on NIH RePORTER →